raloxifene hydrochloride has been researched along with Cataract in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, R; Griffin, JC; Nelson, HD; Smith, ME | 1 |
| Atkins, JN; Bevers, TB; Cecchini, RS; Costantino, JP; Cronin, WM; Fehrenbacher, L; Ford, LG; Ganz, PA; James, J; Jordan, VC; Margolese, RG; McCaskill-Stevens, W; Pajon, ER; Reis, SE; Robidoux, A; Runowicz, CD; Vogel, VG; Wade, JL; Wickerham, DL; Wolmark, N | 1 |
| Atkins, JN; Bevers, TB; Cecchini, RS; Costantino, JP; Cronin, WM; Fehrenbacher, L; Ford, LG; Ganz, PA; James, J; Jordan, VC; Lippman, SM; Margolese, RG; McCaskill-Stevens, W; Pajon, ER; Reis, SE; Robidoux, A; Runowicz, CD; Vogel, VG; Wade, JL; Wickerham, DL; Wolmark, N | 1 |
| Vastag, B | 1 |
| Reeder, JG; Vogel, VG | 1 |
| Chlebowski, RT; Collyar, DE; Pfister, DG; Somerfield, MR | 1 |
3 review(s) available for raloxifene hydrochloride and Cataract
| Article | Year |
|---|---|
Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cataract; Endometrial Neoplasms; Female; Fractures, Bone; Humans; Medication Adherence; Patient Participation; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen; Thromboembolism; Treatment Outcome | 2013 |
Breast cancer risk management.
Topics: Antineoplastic Agents; Breast Neoplasms; Cataract; Endometrial Neoplasms; Female; Humans; Primary Health Care; Quality of Life; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism; United States; Women's Health | 2007 |
American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
Topics: Anticarcinogenic Agents; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Cataract; Endometrial Neoplasms; Estrogen Antagonists; Expert Testimony; Female; Humans; Incidence; Menopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Tamoxifen | 1999 |
2 trial(s) available for raloxifene hydrochloride and Cataract
| Article | Year |
|---|---|
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cataract; Double-Blind Method; Drug Utilization; Endometrial Neoplasms; Estrogens; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Incidence; Middle Aged; Myocardial Ischemia; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism; Uterus | 2010 |
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Topics: Adult; Aged; Breast Neoplasms; Cataract; Cause of Death; Double-Blind Method; Female; Fractures, Bone; Humans; Incidence; Middle Aged; Myocardial Ischemia; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Thrombosis; Uterine Neoplasms | 2006 |
1 other study(ies) available for raloxifene hydrochloride and Cataract
| Article | Year |
|---|---|
Raloxifene prevails in STAR trial, may face easier road to acceptance than previous drugs.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cataract; Contraindications; Controlled Clinical Trials as Topic; Drug Approval; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Thromboembolism; Treatment Outcome; United States; United States Food and Drug Administration; Uterine Neoplasms | 2006 |